Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
Status:
Completed
Trial end date:
2002-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate both the efficacy and toxicity of infusional arsenic
trioxide in the treatment of patients with relapsed or refractory acute promyelocytic
leukemia (APML). In addition, correlation between pharmacokinetic data and both therapeutic
response and therapy-related toxicities will be sought.